Table 3 Treatment-related adverse events during anti-PD(L)-1 and anti-tuberculosis treatment (N=45)
TRAEs | Any grade | Grade 1 | Grade 2 | Grade 3-5 |
|---|---|---|---|---|
Any event | 33 (73.3) | 12 (26.7) | 15 (33.3) | 6 (13.3) |
Hematotoxicity | 27 (60) | 8 (17.8) | 14 (31.1) | 5 (11.1) |
Hepatic toxicity | 4 (8.9) | 3 (6.7) | 1 (2.2) | 0 |
Pneumonitis | 1 (2.2) | 0 | 0 | 1 (2.2) |
Gastrointestinal toxicity | 2 (4.4) | 2 (4.4) | 0 | 0 |
Rash | 4 (8.9) | 3 (6.7) | 1 (2.2) | 0 |
Fatigue | 3 (6.7) | 2 (4.5) | 1 (2.2) | 0 |
Endocrine toxicity | 1 (2.2) | 1 (2.2) | 0 | 0 |
Cardiovascular toxicity | 0 | 0 | 0 | 0 |
Any event leading to discontinuation of ICI | 1 (2.2) | 0 | 0 | 1 (2.2) |
Any event leading to death | 0 | 0 | 0 | 0 |